Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Bercedis Peterson, PhD, MS, Kanti R. Rai, M.D., Thomas S. Lin, MD, PhD, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Andrew R Belch, MD, Richard A. Larson, MD, John C. Byrd, MD

Blood (2011) 118 (21): 289.

https://doi.org/10.1182/blood.V118.21.289.289

Published: 2011

Journal Articles

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.

Jeffrey A. Jones, MD, MPH, Amy Stark, MAS, Weiqiang Zhao, MD PhD, Thomas S. Lin, MD, PhD, Kanti R Rai, MD, Guido Marcucci, MD, Bercedis Peterson, PhD, MS, Richard A. Larson, MD, Nyla A. Heerema, PhD, John C. Byrd, MD

Blood (2011) 118 (21): 1791.

https://doi.org/10.1182/blood.V118.21.1791.1791

Published: 2011

Journal Articles

Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.

Jennifer A Woyach, MD, Amy S Ruppert, Nyla A. Heerema, PhD, Bercedis Peterson, Ph.D, John G. Gribben, MD, DSc, Vicki A. Morrison, MD, Kanti R Rai, MD, Richard A. Larson, MD, John C. Byrd, MD

Blood (2009) 114 (22): 539.

https://doi.org/10.1182/blood.V114.22.539.539

Published: 2009

Journal Articles

Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation

David A. Rizzieri, MD, Robert Storms, Ph.D, Daniel Nikcevich, MD, PhD, Bercedis Peterson, Ph.D, Debashish Misra, MD, Christine Apple, Megan Baker, Cristina Gasparetto, MD, Mitchell Horwitz, MD, John Chute, MD, Ashley Morris, PharmD., Nelson J. Chao, MD

Blood (2008) 112 (11): 342.

https://doi.org/10.1182/blood.V112.11.342.342

Published: 2008

Journal Articles

Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.

Debashish Misra, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis Diehl, MD, Carlos de Castro, MD, Yiping Yang, MD, Cristina Gasparetto, MD, Amy Abernathy, MD, Mitchell Horwitz, MD, Gwynn D. Long, MD, John Chute, MD, Bercedis Peterson, Ph.D, Nelson J. Chao, MD, David A. Rizzieri, MD

Blood (2005) 106 (11): 4623.

https://doi.org/10.1182/blood.V106.11.4623.4623

Published: 2005

Journal Articles

Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy.

John C. Byrd, MD, John G. Gribben, MD, Bercedis Peterson, PhD, Michael R. Grever, MD, Gerard Lozanski, MD, David M. Lucas, PhD, Richard A. Larson, MD, Michael A. Caligiuri, MD, Nyla A. Heerema, PhD

Blood (2004) 104 (11): 476.

https://doi.org/10.1182/blood.V104.11.476.476

Published: 2004

Journal Articles

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia

Mikkael A. Sekeres, Bercedis Peterson, Richard K. Dodge, Robert J. Mayer, Joseph O. Moore, Edward J. Lee, Jonathan Kolitz, Maria R. Baer, Charles A. Schiffer, Andrew J. Carroll, James W. Vardiman, Frederick R. Davey, Clara D. Bloomfield, Richard A. Larson, Richard M. Stone, for the Cancer and Leukemia Group B (CALGB)

Blood (2004) 103 (11): 4036–4042.

https://doi.org/10.1182/blood-2003-09-3118

Published: 2004

NARROW

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.

Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.

Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.

Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy.

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.

Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.

Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.

Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy.

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only